Safety and Bioavailability of Nintedanib in Healthy Males

Phase 1, randomised, single-blind trial of nintedanib intravenous solution in idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 48 hours and Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point up to 48 hours. Started Jun 2009; status: completed.